Prelude Capital Management’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Prelude Capital Management’s Portfolio TARO Stock Details TARO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-617	Closed	-$88K	–	1736
2015 Q3	$88K	Buy	617 +517	+517%	+$72.3K	0.01%	884
2015 Q2	$14K	Buy	+100	New	+$14.3K	﹤0.01%	1522
2015 Q1	–	Sell	-200	Closed	-$30K	–	2249
2014 Q4	$30K	Buy	+200	New	+$29.4K	﹤0.01%	1627
2014 Q3	–	Sell	-594	Closed	-$83K	–	2189
2014 Q2	$83K	Buy	+594	New	+$65.9K	0.01%	1177

Other funds holding TARO

ICM

ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return

MICM

Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

GCM

Greywolf Capital Management Purchase, New York $67.3M AUM 100.05% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Think Investments San Francisco, California $762M AUM 33.1% 1-Year Est. Return

AIM

Assured Investment Management New York $79.5M AUM 115.55% 1-Year Est. Return

Prelude Capital Management's TARO Position: Q4 2015 in Review

Prelude Capital Management sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q4 2015, closing a stake of 617 shares — an estimated $88K sold.

Prelude Capital Management first reported a position in TARO in Q2 2014 and held it in 4 quarters. The position peaked at $88K in Q3 2015. 153 funds tracked by Wall St. Rank hold TARO as of Q4 2015.

Prelude Capital Management reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q4 2015 after selling out during the quarter.
Prelude Capital Management sold 617 Taro Pharmaceutical Industries Ltd. shares in Q4 2015, an estimated $88K.
Prelude Capital Management first reported a position in Taro Pharmaceutical Industries Ltd. in Q2 2014 and held it in 4 quarters.
Prelude Capital Management's Taro Pharmaceutical Industries Ltd. position peaked at $88K in Q3 2015.
153 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q4 2015.

Based on Prelude Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.